Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
Ensem Therapeutics
Ensem Therapeutics
Mayo Clinic
Kivu Bioscience Inc.
AstraZeneca
STORM Therapeutics LTD
Eli Lilly and Company
Neonc Technologies, Inc.
Arcus Biosciences, Inc.
Terremoto Biosciences Inc.
Bristol-Myers Squibb
Seagen Inc.
Pfizer
Radiopharm Theranostics, Ltd
Tizona Therapeutics, Inc
Genentech, Inc.
Clasp Therapeutics, Inc.
Exscientia AI Limited
Normunity AccelCo, Inc.
Eli Lilly and Company
Poseida Therapeutics, Inc.
DualityBio Inc.
MacroGenics
SystImmune Inc.
Eli Lilly and Company
Radiopharm Theranostics, Ltd
ImmunityBio, Inc.
Ocellaris Pharma, Inc.
Fusion Pharmaceuticals Inc.
Innate Pharma
Novartis
Brigham and Women's Hospital
Elephas
OncoNano Medicine, Inc.
GlaxoSmithKline
Fate Therapeutics
Seagen Inc.
University of Pittsburgh
Tanabe Pharma America, Inc.
NeoTX Therapeutics Ltd.
Therorna
West China Hospital
HiFiBiO Therapeutics
DualityBio Inc.
BicycleTx Limited
Volastra Therapeutics, Inc.
M.D. Anderson Cancer Center
LigaChem Biosciences, Inc.
Pfizer
Tempest Therapeutics
Nurix Therapeutics, Inc.